|Articles|March 3, 2008

Post-marketing liver injury reports lead to Tysabri PI update

Liver injury warnings added to natalizumab prescribing information.

Reports of markedly elevated serum hepatic enzymes and elevated total bilirubin in patients receiving natalizumab (

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.


Latest CME